(Health-NewsWire.Net, October 16, 2018 ) Inflammatory bowel disease (IBD) is a group of inflammatory conditions of the colon and small intestine. Crohn's diseaseand ulcerative colitis are the principal types of inflammatory bowel disease. Crohn's disease affects the small intestine and large intestine, as well as the mouth, esophagus, stomach and the anus, whereas ulcerative colitis primarily affects the colon and the rectum. Medical treatment of IBD is individualised to each patient. The choice of which drugs to use and by which route to administer them (oral, rectal, injection, infusion) depends on factors including the type, distribution, and severity of the patient's disease, as well as other historical and biochemical prognostic factors, and patient preferences. For example, mesalazine is more useful in ulcerative colitis than in Crohn's disease. Generally, depending on the level of severity, IBD may require immunosuppression to control the symptoms, with drugs such as prednisone, TNF inhibitors, azathioprine (Imuran), methotrexate, or 6-mercaptopurine. Over the next five years, Expert projects that Inflammatory Bowel Disease will register a xx% CAGR in terms of revenue, reach US$ xx million by 2023, from US$ xx million in 2017.
Request Free Sample Report@ https://www.qurateresearch.com/report/sample/HnM/QBI-LPI-HnM-58616
This report presents a comprehensive overview, market shares and growth opportunities of Inflammatory Bowel Disease market by product type, application, key companies and key regions.
To calculate the market size, Expert considers value generated from the sales of the following segments: The report also presents the market competition landscape and a corresponding detailed analysis of the major players in the market. The key players covered in this report: Bristol-Myers Squibb Company Baxter International Johnson & Johnson Sanofi-Aventis Abbott Laboratories Pluristem Therapeutics Pfizer AstraZeneca Cephalon Amgen
In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key players and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.
Enquiry about Report@ https://www.qurateresearch.com/report/enquiry/HnM/QBI-LPI-HnM-58616
Segmentation by product type: Crohns disease Ulcerative colitis
Segmentation by application: Therapeutic Diagnostics
We can also provide the customized separate regional or country-level reports, for the following regions: Americas United States Canada Mexico Brazil APAC China Japan Korea Southeast Asia India Australia Europe Germany France UK Italy Russia Spain Middle East & Africa Egypt South Africa Israel Turkey GCC Countries
Get Discount@ https://www.qurateresearch.com/report/discount/HnM/QBI-LPI-HnM-58616
Research objectives To study and analyze the global Inflammatory Bowel Disease market size by key regions/countries, product type and application, history data from 2013 to 2017, and forecast to 2023. To understand the structure of Inflammatory Bowel Disease market by identifying its various subsegments. Focuses on the key global Inflammatory Bowel Disease players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years. To analyze the Inflammatory Bowel Disease with respect to individual growth trends, future prospects, and their contribution to the total market. To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks). To project the size of Inflammatory Bowel Disease submarkets, with respect to key regions (along with their respective key countries). To analyze competitive developments such as expansions, agreements, new product launches and acquisitions in the market. To strategically profile the key players and comprehensively analyze their growth strategies
Qurate Business Intelligence
Nehal Chinoy
+919881074592
nehal@qurateresearch.com
Source: EmailWire.Com
|